Inscripta acquires Infinome Biosciences and Sestina Bio

In California, Inscripta, a global leader in genome engineering technology, announced the acquisition of two pioneers of synthetic biology – Infinome Biosciences and Sestina Bio, which advance Inscripta’s strategy to develop and commercialize bio-manufactured products for a broad spectrum of industrial and consumer markets.

The acquisitions demonstrate Inscripta’s confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation.

Prior to the acquisition, Infinome was closely affiliated with Inscripta. Infinome developed the GenoScaler platform, a proprietary strain engineering platform designed to rapidly optimize microbes for biomanufacturing, using Inscripta’s genome engineering technology.